CAN103
/ CANbridge Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 27, 2022
Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease
(clinicaltrials.gov)
- P1/2 | N=40 | Recruiting | Sponsor: CANbridge (Suzhou) Bio-pharma Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Gaucher Disease • Genetic Disorders • Metabolic Disorders • Type 1 Gaucher Disease
July 07, 2022
Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease
(clinicaltrials.gov)
- P1/2 | N=40 | Not yet recruiting | Sponsor: CANbridge (Suzhou) Bio-pharma Co., Ltd.
New P1/2 trial • Gaucher Disease • Genetic Disorders • Metabolic Disorders • Type 1 Gaucher Disease
1 to 2
Of
2
Go to page
1